ERBB2 and cancer: Breast cancer (BC) is one of the most common types of cancer among women and represents 15% of all new cancer cases in the U.S. The standard treatment strategy for BC patients with HER2+ or TNBC is based on a multimodal approach, including trastuzumab (Herceptin), taxane-based therapy, mastectomy, radiation therapy, and targeted therapy [2].